Aspergillosis - Pipeline Review, H1 2017 provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Inquire for Complete Aspergillosis Pipeline Review H1 2017 Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010786

Description of Report:
Aspergillosis (Infectious Disease) pipeline reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics development and enlists all their major and minor projects, dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

Major Companies Discussed In Report Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Biomar Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, Hsiri Therapeutics LLC, iCo Therapeutics Inc, Matinas BioPharma Holdings Inc, Merck & Co Inc, Nanomerics Ltd, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Sigma-Tau SpA, Vical Inc, Visterra Inc.

Drugs Profiles Discussed In Report amphotericin B, Amphotericin B sodium, APX-001, APX-001A, ASP-9726, Aspergillus fumigatus vaccine, BSG-005, C-001, C-016, CD-101, celastrol, Cellullar Immunotherapy for Viral Infections and Fungal Infections, F-901318, itraconazole, KB-425796C, MDN-0018, NP-339, PC-945, posaconazole, PTX-3, SCY-078, SLP-0901, SLP-0904, Small Molecule for Aspergillosis, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Fungal Infections, Small Molecules for Fungal Infections, Small Molecules for Invasive Aspergillosis, Vaccine to Target Glucosylceramide for Fungal Infections, VIS-FNG, VL-2397

Get Discount on Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010786 (This report is available at up to 25% Discount till June 02nd 2017)

Scope: The report provides a snapshot of the global therapeutic landscape of Aspergillosis. The report reviews pipeline therapeutics for Aspergillosis by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews latest news related to pipeline therapeutics for Aspergillosis. Direct Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=1010786 .

Report helps to Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of therapeutics under development for Aspergillosis. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables

• Global Markets Direct Report Coverage
• Aspergillosis - Overview
• Aspergillosis - Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Aspergillosis - Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Aspergillosis - Companies Involved in Therapeutics Development
• Mechanism Of Action
• R&D Progress
• Aspergillosis - Dormant Projects
• Aspergillosis - Discontinued Products
• Aspergillosis - Product Development Milestones
• Featured News & Press Releases
• May 02, 2017: Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
• Apr 25, 2017: Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
• Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings
• Jan 09, 2017: F2G Receives European Orphan Drug Designation for its Lead Candidate F901318.

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: [email protected]